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One puzzling observation in patients affected with
Hutchinson-Gilford progeria syndrome (HGPS), who
overall exhibit systemic and dramatic premature
aging, is the absence of any conspicuous cognitive
impairment. Recent studies based on induced
pluripotent stem cells derived from HGPS patient
cells have revealed a lack of expression in neural
derivatives of lamin A, a major isoform of LMNA
that is initially produced as a precursor called
prelamin A. In HGPS, defective maturation of a
mutated prelamin A induces the accumulation of
toxic progerin in patient cells. Here, we show that a
microRNA, miR-9, negatively controls lamin A and
progerin expression in neural cells. This may bear
major functional correlates, as alleviation of nuclear
blebbing is observed in nonneural cells after miR-9
overexpression. Our results support the hypothesis,
recently proposed from analyses in mice, that
protection of neural cells fromprogerin accumulation
in HGPS is due to the physiologically restricted
expression of miR-9 to that cell lineage.
INTRODUCTION
Hutchinson-Gilford progeria syndrome (HGPS or progeria) is
an extremely rare disease characterized by phenotypic fea-
tures of premature and accelerated aging in children (Henne-
kam, 2006). HGPS is typically caused by a de novo transition
(c.1824C > T) in LMNA (De Sandre-Giovannoli et al., 2003; Eriks-
son et al., 2003), encoding major components of the nuclear
lamina, the lamins A and C (Burke and Stewart, 2006). While
apparently silent (p.G608G), the HGPS mutation activates
a cryptic splicing site leading to the production and accumula-
tion of progerin, a truncated form of prelamin A, the lamin Aprecursor (De Sandre-Giovannoli et al., 2003; Eriksson et al.,
2003). Progerin is aberrantly farnesylated and leads to various
subcellular abnormalities when it accumulates in HGPS nuclei.
These defects include misshapen nuclei, changes in spatial
distribution of nuclear pore complexes (Goldman et al., 2004),
chromatin disorganization (Columbaro et al., 2005), genomic
instability (Liu et al., 2005), and premature cell senescence
(Navarro et al., 2006). HGPS-affected patients develop cardio-
vascular disease, heart failure, and stroke, uniformly leading to
death at a mean age of 13 years old. While most of the tissues
and organs are affected with defects reminiscent of aging (Mer-
ideth et al., 2008), it is intriguing that cognitive functions are
preserved, suggesting a remarkable sparing of central nervous
system through the entire patient’s life course. The molecular
bases have been sought here, by taking the opportunity of
obtaining neural cells in vitro from patients affected with HGPS
through derivation of induced pluripotent stem cells (iPSC).
Over the past 10 years, molecular mechanisms of HGPS have
mostly been approached in vitro using peripheral cells—geneti-
cally modified or not—issued from skin, blood, or bone marrow
(Misteli and Scaffidi, 2005; Paradisi et al., 2005). In several
instances, these cells were not directly relevant for extrapolation
to the behavior of other cell types, especially neural cell lineages.
Meanwhile, previous reports had revealed the absence of lamin
A expression in chicken and mouse embryonic brains (Lehner
et al., 1987; Ro¨ber et al., 1989). The recent emergence of the
iPSC technology has rapidly prompted thederivation of a number
of cell lines derived fromHGPS patients, increasing considerably
the number of cell types of interest (Ho et al., 2011; Liu et al.,
2011a, 2011b; Zhang et al., 2011). Among them, a particular
focus was set to neural cells that have allowed authors to
confirm, in humans, the absence of a significant expression of
lamin A in cells of the neural lineage in vitro, and, as an expected
functional correlation, the subsequent lack of nuclear blebbing
(Zhang et al., 2011). However, molecular mechanisms at the
origin of this specific preservation of cells of the neural lineage
still remain to be elucidated. Recently, Loren Fong and col-
leagues have gone one step further by proposing miR-9 asCell Reports 2, 1–9, July 26, 2012 ª2012 The Authors 1
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Figure 1. Molecular Characterization of Control and HGPS iPSC
(A) qRT-PCR analysis of pluripotency and self-renewal markers OCT4, LEFTB, NANOG, CRIPTO, DNMT3B in control and HGPS fibroblasts and iPSC. Data are
normalized on teratocarcinoma cells (EP2102). Each histogram represents the means ± SD of three independent experiments.
(B) Flow cytometry analysis of pluripotency and self-renewal markers TRA 1-81 and SSEA4 in fibroblasts in control and HGPS fibroblasts and iPSC. Values
indicate means ± SD of three independent experiments.
(C) Immunostaining of lamin A/C (JOL2 and ab8984 antibodies) and lamin B1 and pluripotency and self-renewal markers OCT4, TRA 1-81, and SSEA4 in HGPS
fibrobasts, undifferentiated control and HGPS iPSC. *Boxes represent higher magnification. Scale bar is 50 mm.
See also Figure S1.a potential regulator of lamin A expression in mouse neural
cells (Jung et al., 2012). These authors have associated the
absence of lamin A in murine neurons to a regulation by micro-
RNAs and identified miR-9, a neural specific microRNA, as an
effective regulator. Here, we have extended those results to
neural precursors and neurons of HGPS patients, using the
iPSC technology.
RESULTS
iPSC were generated from HGPS and control patients fibro-
blasts (Figures 1A and 1B). As previously described, A-type
lamins were absent from undifferentiated iPSC (Figure 1C).
In contrast, their expression was observed in a variety of
iPSC-derived cells including keratinocytes, melanocytes, retinal
pigment epithelial cells, and mesenchymal stem cells (MSC-2 Cell Reports 2, 1–9, July 26, 2012 ª2012 The AuthorsiPSC) (Figures 2A and 2B; Table S1). Because MSC derived
from HGPS iPSC presented the commonly described abnor-
malities of HGPS iPSC derivatives, namely, loss of prolif-
eration capacities, premature senescence and nuclear blebbing
(Figures S1A–S1E), we have used, thereafter, these cells as a
‘‘positive control’’ for comparison with cells of neural lineages.
Differentiation of iPSC along the neural lineage was obtained
for both control and HGPS cell lines, up to near-homogeneity
following their differentiation into neural stem cells (NSC-iPSC),
and after terminal differentiation into telencephalic neurons
(Neurons-iPSC) (Figures S2A–S2C). Immunostaining and flow
cytometry analysis using both anti-lamins A/C and specific
anti-lamin A antibodies, confirmed the absence of these lamins
in NSC-iPSC in contrast to a high expression of lamin B1 (Figures
2A and 2B and Figure S2D). The lack of lamins A/C appeared in
neurons of different subtypes, as demonstrated by specifically
Figure 2. Characterization of Lamins Expression Profile in iPSC Derivatives
(A) Lamin A/C immunostaining (JOL2 antibody) in HGPS fibrobasts, undifferentiated HGPS iPSC and its derivatives into mesenchymal stem cells (MSC-iPSC),
melanocytes (Mel-iPSC), keratinocytes (Ker-iPSC), retinal pigment epithelial cells (RPE-iPSC), astrocytes (Astrocytes-iPSC), neural stem cells (NSC-iPSC),
neurons (Neurons-iPSC) and motoneurons (Motoneurons-iPSC). *Boxes represent higher magnification. Scale bar is 50 mm.
(B) Flow cytometry analysis of lamin A/C (JOL2 antibody) and lamin B1 expression in fibroblasts, iPSC,MSC-iPSC, NSC-iPSC andNeurons-iPSC. Values indicate
means ± SD of three independent experiments.
See also Figure S2.differentiating iPSC into motoneurons, but did not extend to
other neural derivatives, such as astrocytes (Figure 2A).
Our study was built on the working hypothesis of an involve-
ment of microRNAs in the neural protection observed in progeria.
As a first step, three different prediction software (Target Scan,
miRDB, and miRanda) were combined in order to align the lamin
A 30 untranslated region (UTR) sequence with all known micro-RNAs seed sequences. Computational alignments have identi-
fied two microRNAs that were candidates for targeting the lamin
A 30 UTR but not lamin C 30 UTR: miR-129-5p and miR-9
(Figure 3A; Figures S3A and S3B). The latter has immediately at-
tracted our attention as this microRNA is considered as the key
player in neural development (Leucht et al., 2008; Yoo et al.,
2009) and neural cell behavior (Ambasudhan et al., 2011; DeCell Reports 2, 1–9, July 26, 2012 ª2012 The Authors 3
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Figure 3. miR-9 Regulates Lamin A and Progerin Expression
(A) Predictive alignment of microRNAs potentially targeting the 30 UTR sequence of lamin A using three independent algorithms: TargetScan, miRanda, and
miRDB.
(B) qRT-PCR analysis of miR-9 in control and HGPS iPSC, fibroblasts, MSC-iPSC, NSC-iPSC, and Neurons-iPSC. Values represent the means ± SD of three
independent experiments.
(C) Western blot analysis of lamin A/C (JOL2 antibody) and b-actin expression in control and HGPS MSC-iPSC transfected with a premiR control (Mock) or
premiR-9.
(D) and (E) Quantification by western blot analysis of lamin A/C and b-Actin expression in control and HGPS MSC-iPSC transfected with a premiR control (Mock)
or premiR-9. *p value < 0.05.
(F) Luciferase activity of control MSC-iPSC transfected or not with lamin A-Luc 30 UTR plasmid in presence of a premiR control (Mock), premiR-203, anti-miR-9, or
premiR-9. *p value < 0.05.
(G) Sequences alignment of the normal and mutated lamin A 30 UTR.
(H) Luciferase activity of control MSC-iPSC transfected or not with the normal or mutated lamin A-Luc 30 UTR plasmids in presence of a premiR control (Mock) or
premiR-9. Values represent the means ± SD of three independent experiments. *p value < 0.05.
See also Figure S3.
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Figure 4. miR-9 Mediated Improvement of HGPS Nuclear Abnormalities
(A) Lamin A/C immunostaining (JOL2 antibody) in HGPSMSC-iPSC transfectedwith a premiR control (Mock) or premiR-9. *Boxes represent highermagnification.
Scale bar is 50 mm.
(B) Quantification of nuclear abnormalities (lamin A/C immunostaining with JOL2 antibody) in HGPS MSC-iPSC transfected with a premiR control (Mock) or
premiR-9. Values represent the means ± SD of two hundreds nuclei in three independent experiments. *p value < 0.05.
(C) Quantification of nuclear abnormalities HGPS MSC-iPSC transfected with increasing concentrations of premiR-9. Values represent the means ± SD of 200
nuclei in three independent experiments. *p value < 0.05.
See also Figure S4.Pietri Tonelli et al., 2008; Delaloy et al., 2010; Zhao et al., 2009).
We therefore dedicated further experiments toward validating
the potential involvement of miR-9. Accordingly, quantitative
real-time PCR (qRT-PCR) revealed that miR-9 was consistently
expressed in NSC-iPSC and Neurons-iPSC, but not in fibro-
blasts, undifferentiated iPSC or MSC-iPSC (Figure 3B). In order
to demonstrate the functional impact of miR-9 on lamins A/C
expression and HGPS molecular defects, gain- and loss-of-
function experiments using premiRs and anti-miRs were per-
formed in MSC-iPSC. These cells were used to avoid any bias
caused by a potential variation in endogenous miR-9 content
since they do not physiologically express miR-9 and, in contrast,
strongly express lamins A/C. Western blot quantification of
A-type lamins revealed that, as compared to untreated controls,
premiR-9 transfected cells, that overexpressed the microRNA,
exhibited a decrease of 66% in the lamin A protein content.
This negative regulation was specific to lamin A because, in
contrast, lamin C exhibited a 50% increase under treatment
with premiR-9 (Figures 3C and 3D). The same experiments
were carried out in HGPS MSC-iPSC providing similar results,
with miR-9 overexpression eliciting a 35% decrease in lamin A
and a 55% increase in lamin C. The overexpression of miR-9
additionally promoted a 38% decrease in progerin expression
in affected cells (Figure 3E). In a search for molecular mecha-
nisms of action, the direct targeting of miR-9 on lamin A 30
UTR was confirmed and quantified by transfecting MSC-iPSC
with a plasmid that contained a luciferase gene under the control
of the lamin A 30 UTR. Measures of luminescence were per-
formed 72 hr after co-transfection with either a premiR or anti-
miR for miR-9 revealing that overexpression of miR-9 microRNAwas sufficient on its own to decrease the luciferase activity by
up to 40% as compared to controls and anti-miR-9-treated
MSC-iPSC (Figure 3F). As a control of miR-9 specificity, the
two lamin A 30 UTR sites targeted by miR-9 were mutated, and
no effect of miR-9 overexpression was then recorded (Figures
3G and 3H).
In the literature, decrease of progerin expression has been
associated with a decrease in nuclear blebbing in patients’ cells
(Cao et al., 2011; Huang et al., 2005; Osorio et al., 2011). Accord-
ingly, quantification of lamins A/C immunostaining revealed that
whereas 60% of control and anti-miR-9 treated HGPS MSC-
iPSC presented abnormally shaped nuclei, the overexpression
of miR-9 induced a significant decrease of bleb containing nuclei
to 48% (Figures 4A, 4B, and S4A). This effect was dose-depen-
dent, as shown by transfecting cells with premiR-9 at succes-
sively higher concentrations (Figures 4C, S4B, and S4C).
DISCUSSION
Altogether, our results shed light on a unique molecular mecha-
nism that specifically protects neurons in patients with Hutchin-
son-Gilford progeria syndrome from the defective prelamin A
processing. MicroRNAs play key roles in the specific differentia-
tion and maturation of cells and tissues in various systems
(Houbaviy et al., 2003; Judson et al., 2009; Krichevsky et al.,
2006; Lee et al., 1993; Ruvkun, 2001; Smirnova et al., 2005;
Suh et al., 2004) including pluripotent stem cells commitment
as we recently demonstrated for miR-203 in the early stages of
keratinocytes development (Nissan et al., 2011a) or for miR-
125 in neural differentiation (Boissart et al., 2012). These dataCell Reports 2, 1–9, July 26, 2012 ª2012 The Authors 5
are consistent with the strict neural specificity of miR-9 during
the first steps of mouse brain development (Smirnova et al.,
2005), as well as during neural differentiation from ES cells in
the mouse (Krichevsky et al., 2006) as in the Human (Delaloy
et al., 2010). Over the past few years, several functional studies
highlighted not only the neural-specific expression of miR-9, but
its key role in the regulation of numerous processes related to
neural differentiation (Zhao et al., 2009), proliferation, and migra-
tion (Delaloy et al., 2010). On the basis of these observations and
according to the established key role of miR-9 in neural develop-
ment, we hypothesized and demonstrated that this microRNA
regulates lamin A expression in neural progenies, providing
insight into the tissue selectivity of HGPS.
Our data correlate to the recently emitted hypothesis that
miR-9 regulates mouse prelamin A expression revealing more-
over that this molecular mechanism is conserved in humans
and acts as a protective mechanism of HGPS neurons. In this
context, lamin A gene extinction would physiologically be part
of that general ‘‘neuralizing activity’’ of miR-9 showing that the
singular molecular constitution of neural cells’ nuclear envelope
is, by itself, sufficient to significantly reduce the occurrence of
dysmorphic nuclei that are otherwise elicited by the HGPSmuta-
tion in most cells. As it was previously described (Zhang et al.,
2011), lamins A/C were, however, also absent from undifferenti-
ated iPSC, i.e., in the absence of a significant expression of
miR-9, suggesting the existence of others molecular regulators
of A-type lamins expression in pluripotent stem cells. On the
basis of our findings, we propose miR-9 as a member of the
emerging list of microRNAs that have been associated with
HGPS pathophysiology. In fact, recently, Carlos Lo´pez-Otı´n
and colleagues have shown that miR-1 expression was upregu-
lated in HGPS fibroblasts, impacting cell function by reducing
IGF-1 synthesis and causing a dysregulation of this major
life span regulator (Marin˜o et al., 2010). Similarly, another family
of microRNA, miR-29, was shown to be upregulated in
Zmpste24/ progeroid mice, altering the activity of Ppm1d
phosphatase, which in turn enhanced p53 activity (Ugalde
et al., 2011). Compared to these data, miR-9 has clearly a unique
function as it impacts the disease cell phenotype at physiological
levels, protecting changes in one specific cellular lineage. We
thus speculate that the absence of cognitive impairment in
children affected by progeria is due to a beneficial effect of
miR-9 as a specific and physiological regulator of neural devel-
opment. Such relations between microRNAs specificity and
diseases may be applied to other metabolic diseases and other
tissues, in whichmicroRNAs similarly play key roles in the control
of organogenesis (Bartel, 2009; Lee et al., 2004).
Over the years, several studies have highlighted the exis-
tence of a small number of tissue-specific microRNAs that
are key players during development in vertebrates, including
miR-203 for the entire sequence of skin embryogenesis (Nissan
et al., 2011a; Yi et al., 2006, 2008), miR-1 and miR-133 in
muscle formation (Townley-Tilson et al., 2010) as well as miR-
155 and miR-181 in hematopoietic differentiation (Vasilatou
et al., 2010). Whereas potential roles of microRNAs in the
expression of a pathology are currently being investigated,
our results support a complementary approach in the search
for protective mechanisms, in particular when tissues or organs6 Cell Reports 2, 1–9, July 26, 2012 ª2012 The Authorsseem to be specifically unaffected by supposedly ubiquitously
expressed pathological agents, as illustrated by the example
of progeria.EXPERIMENTAL PROCEDURES
Fibroblasts Reprogramming
Fibroblasts used in this study were isolated from patient biopsies performed in
the Assistance Publique Hoˆpitaux de Marseille (13-5968, 13-8243) or provided
by Coriell Institute (Camden, USA) (DM4603 and AG11513, AG01972). One
control (DM4603) and two HGPS (AG01972 and 13-8243) cell lines were
successfully reprogrammed to iPSC whereas the most affected HGPS cells
were not (13-5968, AG11513). Three independent iPSC lines were derived
from one control (DM4603) and one HGPS (13-8243) from patients using
Yamanaka’s original method with OCT4, KLF4, SOX2, c-Myc, transferred
using retroviral vectors (Takahashi et al., 2007). The iPSC lines were amplified
up to the 15th passage before differentiation.
Pluripotent Stem Cells Culture and Differentiation
Control and HGPS iPSC as well hESC from two cell lines, SA01 (Cellartis,
Go¨tenborg, Sweden) and H9 (Wicell, Madison, WI) were grown on STOmouse
fibroblasts, inactivated with 10 mg/ml mitomycin C, seeded at 30000/cm2 and
grown as previously described (19). For differentiation, hESC and iPSC were
differentiated into mesenchymal stem cells (MSC-iPSC) keratinocytes (Ker-
iPSC), melanocytes (Mel-iPSC), and retinal pigment epithelial cells (RPE
iPSC) using directed protocols for differentiation previously published by our
group (Giraud-Triboult et al., 2011; Guenou et al., 2009; Nissan et al.,
2011b). Neuronal differentiation was performed according to an adaptation
of the dual SMAD inhibitor cocktail (Noggin, SB431542) described by Cham-
bers and colleagues (Chambers et al., 2009). For amplification, NSC-iPSC
were cultivated in N2B27 medium (Invitrogen, Carlsbad, CA) supplemented
with FGF2, EGF, and brain-derived neurotrophic factor (BDNF) for 10–20
passages and terminally differentiated in the neurons-iPSC after 21 days of
starvation with the mitotic growth factors (FGF2 and EGF). For motoneurons
differentiation, embryoid bodies (EBs) were generated in presence of the
SMAD inhibitors and caudalized by addition of retinoic acid, BDNF, ascorbic
acid. After 11 days EBs were treated with Sonic Hedgehog and after
21 days cells were dissociated to be cultured up to 30 days in presence of
the same medium supplemented with Rock inhibitor and glial cell line-derived
neurotrophic factor (GDNF). For astrocytes generation, inhomogeneous
population of motoneurons were then switched to N2B27 medium supple-
mented with ascorbic acid, BDNF, GDNF, and ciliary neurotrophic factor for
an additional 10 days.
mRNA Purification and qRT-PCR
Total RNA from pluripotent stem cells and their derivatives were isolated using
an RNeasyMini extraction kit (QIAGEN, Courtaboeuf, France) according to the
manufacturer’s protocol. An on-column DNase I digestion was performed to
avoid genomic DNA amplification. RNA level and quality were checked using
the Nanodrop technology. A total of 500 ng of RNA was used for reverse
transcription using the Superscript III reverse transcription kit (Invitrogen).
qRT-PCR analysis was performed using a LightCycler 480 system (Roche,
Basel Switzerland) and SYBR Green PCR Master Mix (Roche) following the
manufacturer’s instructions. Quantification of gene expression was based
on the DeltaCt Method and normalized to 18S expression. PCR primers are
listed in Table S2.
MicroRNAs Extraction and TaqMan Assay
MicroRNAs were extracted using miRVana extraction kit (Applied Biosys-
tems, Foster City, USA) according to the manufacturer’s protocol after
phenol-chloroform and column purification. Individual TaqMan microRNA
assays were performed on ABI 7900 (Applied Biosystems) with a no UNG
no Amperase master mix (Applied Biosystems) according to the manufac-
turer’s protocol. Results were normalized against RNU 48 a small nucleolar
RNAs (snoRNAs).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (15 min, room temperature) before
permeabilization and blocking in PBS supplemented with 0.1% Triton X-100
and 1% BSA (Sigma-Aldrich, St. Louis, MO). Primary antibodies were
incubated 1 hr at room temperature in blocking buffer. Antibodies included
mouse anti-lamin A/C (JOL2, Millipore, Billerica, MA), rabbit anti-lamin A/C
(ab8984, Abcam, Cambridge, UK), rabbit anti-lamin A (Santa Cruz Biotech-
nology, Santa Cruz, CA), mouse anti-lamin B1 (Abcam), mouse anti-OCT4
(Abcam), rabbit anti-K14 (Novocastra, Wetzlar, Germany), rabbit anti-TYRP1
(LifeSpan BioSciences, Seattle, WA), mouse anti-ZO-2 (Abcam), rabbit anti-
Pax6 (Covance, Princeton, NJ), mouse anti-Nestin (Millipore), rabbit anti-Nes-
tin (Millipore), rabbit anti-Sox2 (Invitrogen), rabbit anti-Tuj1 (Covance), rabbit
anti-OCT4 (Santa Cruz Biotechnology), rabbit anti-TRA 1-81 (Abcam), rabbit
anti-SSEA 4 (Abcam), mouse anti-ALCAM (BD Biosciences), mouse anti-
Integrin b1 (BD Biosciences), mouse anti-Hyaluronate receptor (BD Biosci-
ences), mouse anti-SH3/NT5E (BD Biosciences), rabbit anti-GFAP (Dako),
mouse anti-MNR2 or HB9 (DHSB), and mouse anti-Pax3 (Millipore). Cells
were stained with the species-specific fluorophore-conjugated secondary
antibody (Invitrogen) (1 hr, room temperature); nuclei were visualized with
DAPI. Three independent experiments were performed using each cell type.
Photographs were taken using a Zeiss microscope equipped with epi-fluores-
cence illumination.
Flow Cytometry Analysis
Cells were detached from culture plates using Trypsin 0.05% EDTA
(Invitrogen) and fixed in 4% paraformaldehyde (15 min, room temperature).
After PBS wash, cells were either permeabilized with 0.1% Saponin (Sigma-
Aldrich). Primary antibodies diluted at 1:100 were incubated (1 hr, room
temperature) in PBS containing 0.1% FCS. Isotype-specific controls were
carried out using no primary antibody. Species-specific secondary antibodies
were added (1 hr, room temperature) and the cells were analyzed on a
FACScalibur using CellQuest software (BD Biosciences, Franklin Lakes, NJ).
The number of events analyzed for each experiment was 10,000. Three inde-
pendent experiments were performed for each cell line.
Western Immunoblotting
Whole-cell lysates of MSC-iPSC were collected, separated by SDS-PAGE,
and transferred onto nitrocellulose membranes by electroblotting. Blots
were blocked in 10% skim milk (Bio-Rad) in Tween 0.1% Tris-buffered saline
1 hr at room temperature. The primary antibodies used were a mouse anti-
lamin A/C 1:200 (Millipore, JOL2) or a b-Actin 1/200 000 (Sigma). Membranes
were incubated during the night at 4C. Antigen-antibody binding was de-
tected using horseradish peroxidase-conjugated species-specific secondary
antibodies (GE-Healthcare, Little Chalfont, UK) followed by enhanced chemi-
luminescence western blotting detection reagents (Perkin-Elmer, Waltham,
MA). Densitometric analysis was performed and lamin A/C ratios were calcu-
lated following normalization to the value for b-Actin.
30 UTR Luciferase Activity
Confirmation of miR-9 binding capacities to the putative 30 UTR binding site of
lamin A utilized a luciferase reporter assay. MSC-iPSC at 80% confluence
were nucleofected with 1 mg of reporter vector pmiR-Target-lamin A 30 UTR,
empty vector pmiR-Target (negative transfection control) or pCMV-GFP
(positive transfection control) using Amaxa nucleofector (Lonza, Basel,
Switzerland). All vectors were provided by OriGene (Rockville, MD). A mutated
version of pmiR-Target-lamin A 30 UTRwas obtained by directedmutagenesis,
following manual instruction of QuikChange Multi-site directed mutagen-
esis kit (Agilent Technology). Both miR-9 recognition sites were mutated:
CCAAAGA (site 1) was replaced by gCttAGA and ACCAAAG (site 2) was
replaced by AgCttAG. Twenty-four hours after nucleofection, MSC-iPSC
were transfected with microRNAs mimics: premiR-9, premiR-203 (unrelated
negative control), premiR-Scramble (negative control or mock), anti-miR-9,
or anti-miR Scramble. All premiRs and antagomiRs (Applied Biosystems)
were transfected at 100 nM using lipofectamin RNAimax (Invitrogen) reagent
according to manufacturer’s protocol. Forty-eight hours after transfection
Steady-Glo luciferase assay reagent (Promega, Madison, WI) was added to
each well and the plate was incubated at room temperature in the dark for30 min. The luciferase signal was measured using an Analyst GT counter
luminometer (Molecular Devices). Data were normalized using measurement
of ATP content using Cell title Glo (Promega), and knockdown was assessed
by calculating luciferase signal ratios for specific miRNA/nontargeting control
(mock).
microRNAs Transfection
PremiRs and antimiRs (Applied Biosystems) were transfected in MSC using
lipofectamin RNAimax (Invitrogen) according to manufacturer’s instructions.
Statistical Analysis
Statistical analysis has been performed by one-way analysis of variance
(ANOVA), using the Dunnet’s comparison test. Values of p < 0.05 were consid-
ered significant (*p < 0.05, **p < 0.01, ***p < 0.001).
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